Cervical cytology biobanking in Europe

International Journal of Biological Markers

Volumn 25, Issue 3, 2010, Pages 117-125

  Arbyn, Marc ^a   Van Veen, Evert Ben ^b   Andersson, Kristin ^c   Bogers, Johannes ^d   Boulet, Gaëlle ^d   Bergeron, Christine ^e   Von Knebel Doeberitz, Magnus ^f   Dillner, Joakim ^c  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b Medlaw Consult   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e LABORATOIRE CERBA   (France)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biobank; Cervical cancer; Cervical cytology; Human papillomavirus; Molecular markers

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

CANCER IMMUNIZATION; CANCER REGISTRY; CANCER SCREENING; CLINICAL PRACTICE; CYTOPATHOLOGY; DATA BASE; DNA SEQUENCE; EUROPE; GENETIC IDENTIFICATION; HEALTH SURVEY; HISTOLOGY; HUMAN; INFORMATION CENTER; MEDICAL ETHICS; MEDICAL RESEARCH; NEOPLASM; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PROTEOMICS; QUALITY CONTROL; REVIEW; SPECTROPHOTOMETRY; STORAGE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 78650846473     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460081002500301     Document Type: Review

References (67)

1. Anttila A, von Karsa L, Aasmaa A, et al. Cervical cancer screening policies and coverage in Europe. Eur J Cancer 2009; 45: 2649-58.
2. Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invase cervical cancer. N Engl J Med 1999; 341: 1633-8.
3. Ylitalo N, Josefsson A, Melbye M, et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000; 60: 6027-32.
4. Zielinski GD, Snijders PJ, Rozendaal L, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001; 85: 398-404. (Pubitemid 32747709)
5. van der Graaf Y, Molijn A, Doornewaard H, Quint W, van Doorn LJ, van den Tweel J. Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol 2002; 156: 158-64.
6. Gunnell AS, Tran TN, Torrang A, et al. Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development. Cancer Epidemiol Biomarkers Prev 2006; 15: 2141-7.
7. Arbyn M, Herbert A, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007; 18: 133-9. (Pubitemid 46934510)
8. Arbyn M, Andersson K, Bergeron C, Bogers JP, von Knebel-Doeberitz M, Dillner J. Cervical cytology biobanks as a resource for molecular epidemiology. In: Dillner J, ed. Methods in biobanking. Springer Science+Business Media: New York, 2010, Chapter 15.
9. Davey DD, Cox JT, Austin RM, et al. Cervical cytology specimen adequacy: patient management guidelines and optimizing specimen collection. J Low Genit Tract Dis 2008, 12: 71-81.
10. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-9.
11. Herbert A, Bergeron C, Wiener H, Schenck U, Klinkhamer PJ, Arbyn M. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007; 18: 213-9.
12. Arbyn M, Anttila A, Jordan J, et al. European guidelines for quality assurance in cervical cancer screening. Second edition - summary document. Ann Oncol 2010; 21: 448-58.
13. Castle PE, Solomon D, Hildesheim A, et al. Stability of archived liquid-based cervical cytologic specimens. Cancer 2003; 99: 89-96. (Pubitemid 36529730)
14. Bergeron C, Cas F, Fagnani F, Didailler-Lambert F, Poveda JD. Human papillomavirus testing with a liquid-based system: feasibility and comparison with reference diagnoses. Acta Cytol 2006; 50: 16-22.
15. Canfell K, Gray W, Snijders PJ, et al. Factors predicting succesful DNA recovery fom archival cervcal smear samples. Cytopathology 2004; 15: 276-82.
16. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004; 112: 854-9.
17. Tarkowski TA, Rajeevan MS, Lee DR, Unger ER. Improved detection of viral RNA isolated from liquid-based cytology samples. Mol Diagn 2001; 6: 125-30.
18. Cuschieri KS, Beattie G, Hassan S, Robertson K, Cubie H. Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium. J Virol Methods 2005; 124: 211-5. (Pubitemid 40138799)
19. Powell N, Smith K, Fiander A. Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J Virol Methods 2006; 137: 58-62.
20. Horvath CA, Boulet G, Sahebali S, et al. Effects of fixation on RNA integrity in a liquid-based cytology setting. J Clin Pathol 2007; 10: 1-13.
21. Dixon EP, King LM, Adams MD, et al. Isolation of RNA from residual BD SurePath liquid-based cytology specimens and detection of HPV E6/E7 mRNA using the PreTectt HPV-Proofer assay. J Virol Methods 2008; 154: 220-2.
22. Murphy PG, Henderson DT, Adams MD, et al. Isolation of RNA from cell lines and cervical cytology specimens stored in BD SurePath preservative fluid and downstream detection of housekeeping gene and HPV E6 expression using real time RT-PCR. J Virol Methods 2009; 156: 138-44.
23. Sambrook J, Russell DW. Molecular cloning: a laboratory manual, Vol 1-3. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 2001.
24. Boulet GA, Horvath CA, Berghmans S, et al. Cervical cytology biobanking: quality of DNA from archival cervical Pap-smears. J Clin Pathol 2008; 61: 637-41.
25. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230: 1350-4. (Pubitemid 16105164)
26. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-317.
27. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′ - 3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 1991; 88: 7276-80.
28. Snijders PJ, Heideman DA, Meijer CJ. Methods for HPV detection in exfoliated cell and tissue specimens. APMIS 2010; 118: 520-8.
29. Sotlar K, Selinka HC, Menton M, Kandolf R, Bultmann B. Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol Oncol 1998; 69: 114-21.
30. Smits HL, van Gemen B, Schukkink R, et al. Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-E7 transcripts. J Virol Methods 1995; 54: 75-81.
31. Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol 2009; 511: 333-59.
32. Doorbar J, Cubie H. Molecular basis for advances in cervical screening. Mol Diagn 2005; 9: 129-42.
33. Khan AM, Singer A. Biomarkers in cervical precancer management: the new frontiers. Future Oncol 2008; 4: 515-24.
34. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer 2009; 125: 2489-96.
35. von Knebel DM. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002; 38: 2229-42.
36. Sahebali S, Depuydt C, Boulet GA, et al. Immunocytochemistry in liquid-based cervical cytology: analysis of clinical use following a cross-sectional study. Int J Cancer 2006; 118: 1254-60 .
37. Wentzensen N, Bergeron C, Cas F, Eschenbach D, Vinokurova S, von Knebel DM. Evaluation of a nuclear score for P16(INK4a)-stained cervical squamous cells in liquid-based cytology samples. Cancer 2005; 461-7.
38. Bergeron C, Wentzensen N, Cas F, Doeberitz MV. The P16INK4a protein: a cytological marker for detecting high grade intraepithelial neoplasia of the uterine cervix. Ann Pathol 2006; 26: 397-402.
39. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of P16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84.
40. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R. Conjunctive P16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2010; 133: 395-406.
41. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003; 3: 267-75.
42. Kuramitsu Y, Nakamura K. Proteomic analysis of cancer tissues: shedding light on carcinogenesis and possible biomarkers. Proteomics 2006; 6: 5650-61.
43. Yim EK, Park JS. Role of proteomics in translational research in cervical cancer. Expert Rev Proteomics 2006; 3: 21-36.
44. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339: b2968.
45. Laukkanen P, Koskela P, Pukkala E, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003; 84: 2105-9.
46. Arbyn M, Raifu AO, Bray F, Weiderpass E, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009; 45: 2640-8.
47. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007; 38: 189-97.
48. Andersson K, Bray F, Arbyn M, et al. The interface of population-based cancer registries and biobanks in etiological and clinical research - current and future perspectives. Acta Oncol 2010 [Epub ahead of print].
49. Lehtinen M, Kaasila M, Pasanen K, et al. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 2006; 119: 2612-9.
50. Dillner J, Arbyn M, Dillner L. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol 2007; 148: 199-207.
51. Cambon-Thomsen A. The social and ethical issues of post-genomic human biobanks. Nat Rev Genet 2004; 5: 866-73. (Pubitemid 39457502)
52. Council of Europe; Committee of Ministers. Recommendation (2006)4 of the Committee of Ministers to member states on research on biological materials of human origin. Available at https://wcd.coe.int/ViewDoc.jsp?id=977859.
53. Organisation for Economic Co-operation and Development (OECD). Guidelines for human biobanks and genetic research databases (HBGRDs), 2009. Available from www.oecd.org/sti/biotechnology/hbgrd.
54. Follesdal A, Wessel RA, Wouters J. Multilevel regulation and the EU: the interplay between global, European and national normative processes. Leiden & Boston: Martinus Nijhoff Publishers, 2008.
55. Van Veen EB, Riegman PH, Dinjens WN, et al. TuBaFrost 3: regulatory and ethical issues on the exchange of residual tissue for research across Europe. Eur J Cancer 2006; 42: 2914-23.
56. Borisch B. Tissue banking in a regulated environment - Does this help the patient? Part 2 - Patient views and expectations (including the EUROPA DONNA Forum UK Position). Pathobiology 2007; 74: 223-6.
57. Vermeulen E, Schmidt MK, Aaronson NK, et al. Opt-out plus, the patients' choice: preferences of cancer patients concerning information and consent regimen for future research with biological samples archived in the context of treatment. J Clin Pathol 2009; 62: 275-8.
58. Hansson MG, Dillner J, Bartram CR, Carlson JA, Helgesson G. Should donors be allowed to give broad consent to future biobank research? Lancet Oncol 2006; 7: 266-9.
59. Hansson MG. Building on relationships of trust in biobank research. J Med Ethics 2005; 31: 415-8.
60. Hansson MG. Ethics and biobanks. Br J Cancer 2009; 100: 8-12.
61. van Veen EB. Obstacles to European Research projects with data and tissue: solutions and further challenges. Eur J Cancer 2008; 44: 1438-50.
62. Johnsson L, Hansson MG, Eriksson S, Helgesson G. Patients' refusal to consent to storage and use of samples in Swedish biobanks: cross sectional study. BMJ 2008; 337: a345-7.
63. Johnsson L, Hansson MG, Eriksson S, Helgesson G. Optout from biobanks better respects patients' autonomy. BMJ 2008; 337: a1580.
64. Kettis-Lindblad A, Ring L, Viberth E, Hansson MG. Genetic research and donation of tissue samples to biobanks. What do potential sample donors in the Swedish general public think? Eur J Public Health 2006; 16: 433-40.
65. Kettis-Lindblad A, Ring L, Viberth E, Hansson MG. Perceptions of potential donors in the Swedish public towards information and consent procedures in relation to use of human tissue samples in biobanks: a population-based study. Scand J Public Health 2007; 35: 148-56.
66. Helgesson G, Dillner J, Carlson J, Bartram CR, Hansson MG. Ethical framework for previously collected biobank samples. Nat Biotechnol 2007; 25: 973-6.
67. Arbyn M, Wallyn S, Van Oyen H, Nys H, Dhont J, Seutin B. The new privacy law in Belgium: a legal basis for organised cancer screening. Eur J Health Law 1999; 6: 401-7.